Gonadotropin-releasing hormone agonist (leuprolide acetate) induced ovarian hyperstimulation syndrome in a woman undergoing intermittent hemodialysis.
Moderate ovarian hyperstimulation syndrome occurred after LA was administered to control menorrhagia in an anephric woman who required hemodialysis. We postulate that women who require dialysis may be at special risk for the development of this syndrome.
Hampton
H L
HL
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216.
Whitworth
N S
NS
Cowan
B D
BD
D000328:Adult; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D016729:Leuprolide; D008595:Menorrhagia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010048:Ovarian Cysts / Q000097:blood / Q000150:complications; D010053:Ovary / Q000187:drug effects*; D006435:Renal Dialysis; D013577:Syndrome; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D003692:Delayed-Action Preparations; D006728:Hormones; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C019176:Tryptal; D005640:Follicle Stimulating Hormone; D016729:Leuprolide